Viracta Therapeutics (FRA:RYI) Accounts Payable & Accrued Expense : €9.13 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Accounts Payable & Accrued Expense?

Viracta Therapeutics's quarterly accounts payable & accrued expense declined from Dec. 2023 (€11.75 Mil) to Mar. 2024 (€10.49 Mil) and declined from Mar. 2024 (€10.49 Mil) to Jun. 2024 (€9.13 Mil).

Viracta Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 (€7.70 Mil) to Dec. 2022 (€9.19 Mil) and increased from Dec. 2022 (€9.19 Mil) to Dec. 2023 (€11.75 Mil).

Viracta Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Viracta Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Accounts Payable & Accrued Expense Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

4.04

7.70

9.19

11.75

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial													9.72	10.18	11.75	10.49	9.13

Viracta Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.